Highlights

  • Cyclopharm reported first-half 2026 revenue of $17.5 million, an increase of 14%.
  • US Technegas revenue increased 74% to $2.1 million in the same period.
  • Revenue-generating US sites reached 83 by 12 August 2026, compared with 70 at June-end.
  • Updated lung imaging guidelines published in July identify Technegas as generally preferred when available.
  • An October 2026 Chinese clinical consensus also identified Technegas as the preferred ventilation agent.

Cyclopharm Limited (ASX:CYC) develops and supplies Technegas, a lung ventilation imaging technology used in nuclear medicine, alongside distribution activities through its healthcare operations. Its 2026 disclosures show an expanding US installation base, higher first-half revenue and new clinical guidance referencing Technegas. Hospital implementation and recurring consumable demand remain central.

Clinical Guidance Broadens Recognition

On 29 July 2026, Cyclopharm Limited (ASX:CYC) reported publication of updated international ventilation-perfusion lung imaging guidance. The guidelines describe Technegas as “generally preferred when available” for ventilation imaging. They also discuss three-dimensional SPECT and SPECT/CT techniques and uses of ventilation imaging extending beyond pulmonary embolism. The publication establishes clinical guidance, rather than a requirement for hospitals to adopt the product.

On 7 October 2026, the company announced that a consensus issued by seven Chinese medical bodies recommended Technegas as the preferred ventilation agent for pulmonary embolism imaging. The consensus described an alternative aerosol agent for situations in which Technegas is unavailable. These recommendations relate to clinical practice; they do not themselves measure future sales or guarantee procurement.

US Hospital Rollout and Recurring Revenue

Cyclopharm Limited (ASX:CYC) had 70 revenue-generating US primary sites at 30 June 2026, compared with 35 a year earlier. By 12 August, that total had reached 83. Its August presentation identified 1,684 actively engaged US pipeline sites, although prospective sites at different stages of review or contracting should not be treated as installed equipment.

The company also announced an immediate 11-site Technegas rollout at University Hospitals in July 2026. Commercial activity combines device placement with access fees and single-patient consumables. This operating model links use of installed systems to recurring revenue, while installation schedules, contracting and clinical workflows influence the timing of receipts.

First-Half Results and Cash Position

For the six months ended 30 June 2026, Cyclopharm Limited (ASX:CYC) reported total revenue of $17.5 million, up 14% from the corresponding period. US Technegas revenue reached $2.1 million against $1.2 million in the prior-year half, an increase of 74%. Revenue from Technegas outside the US rose 13% to $7.3 million, while third-party distribution revenue reached $8.1 million, up 4%.

The gross margin increased to 56.3% from 53.5%, reflecting a greater contribution from Technegas. However, the net loss after tax widened to $8.8 million from $7.7 million. Cyclopharm ended June 2026 with $12.2 million in cash. These results show revenue expansion alongside continuing losses and expenditure associated with the US commercial rollout.

Execution Factors and Commercial Constraints

For Cyclopharm Limited (ASX:CYC), the distinction between clinical acceptance and commercial implementation remains important. Guidelines can inform medical decisions, but individual healthcare systems still need to complete purchasing, installation, training and routine patient workflows. The 2026 US site figures provide an observable measure of deployment, whereas the broader pipeline represents potential activity rather than confirmed revenue.

Financial performance also depends on the rate at which installed systems are used, the balance between equipment and consumables revenue, and the cost of maintaining sales and service operations. Regulatory, hospital-budget and operational requirements can influence the timing of additional implementations. The company’s reported cash and half-year loss therefore remain relevant alongside revenue and installed-site growth.

Key Insights

Cyclopharm Limited (ASX:CYC) entered the second half of 2026 with more US revenue-generating sites, increased Technegas sales and explicit recognition in updated international imaging guidance. Its October Chinese consensus announcement added another clinical reference. The central distinction is between documented product adoption and the further hospital implementation needed to translate clinical recognition into sustained commercial revenue.